After Merck News Today

It wasn't long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn't come together, and the biotech eventually sold to Merck for $11.5 billion. Now, BMS has its eyes on another target, Bloomberg reports.

Beeler was not part of the research team.  “We are very pleased to share our initial Phase 2 infectivity data at this important conference, which remains at the forefront for critical clinical scientific information in infectious diseases,” said Dr. Wendy Painter, chief medical officer of Ridgeback Biotherapeutics, in a news release.At a time where there is an unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.” Beeler’s message to Hoosi...

Merck is in talks to potentially help with producing COVID-19 vaccines, a spokesman said. (Merck) After Merck & Co. got off to a late start in the COVID-19 vaccine race and made an early exit, the drug giant is in talks to aid the global vaccine manufacturing effort. The drugmaker is “actively involved” in discussions with governments, health agencies and other pharmaceutical companies to “identify the areas of pandemic response where we can play a role, including potential support for pr...